标题
Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy
作者
关键词
-
出版物
Cancers
Volume 11, Issue 3, Pages 421
出版商
MDPI AG
发表日期
2019-03-27
DOI
10.3390/cancers11030421
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
- (2018) Ann S. LaCasce et al. BLOOD
- Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
- (2018) Tycel J. Phillips et al. BLOOD
- A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
- (2018) Eric Van Den Neste et al. HAEMATOLOGICA
- Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
- (2018) Catherine M. Bollard et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
- (2018) Eric Van Den Neste et al. HAEMATOLOGICA
- Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes
- (2017) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
- (2017) Robert Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma
- (2017) Bei Hu et al. LEUKEMIA & LYMPHOMA
- Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma
- (2016) Anna Alperovich et al. CANCER JOURNAL
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma
- (2016) Peter Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
- (2015) Robert Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
- (2015) Alison J Moskowitz et al. LANCET ONCOLOGY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event
- (2014) M. D. Gandhi et al. BLOOD
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
- (2013) Y. Oki et al. CLINICAL CANCER RESEARCH
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines
- (2012) M. Lemoine et al. BLOOD
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
- (2012) Alison J. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
- (2011) T. A. Fehniger et al. BLOOD
- Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
- (2011) C. H. Moskowitz et al. BLOOD
- How I treat relapsed and refractory Hodgkin lymphoma
- (2011) J. Kuruvilla et al. BLOOD
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
- (2011) Anas Younes et al. LANCET ONCOLOGY
- A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
- (2010) Patrick B. Johnston et al. AMERICAN JOURNAL OF HEMATOLOGY
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histone deacetylase inhibitors: Potential in cancer therapy
- (2009) P.A. Marks et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide for the Treatment of B-Cell Malignancies
- (2008) Asher A. Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More